Patients who have received prior pelvic radiotherapy
Prior pelvic radiotherapy or prostatectomy
Previous pelvic radiotherapy
Clinically large pelvic masses reaching above the umbilicus
Pelvic organ prolapse greater than stage II
Prior reconstructive pelvic surgery involving mesh for prolapse
Histological or cytological confirmation of locally recurrent or metastatic rectal adenocarcinoma\r\n* Note: Patients with locally recurrent/persistent disease within the pelvis after primary therapy (chemotherapy, surgery, and/or radiotherapy) are eligible\r\n* Note: Patients who have had prior pelvic radiotherapy with a total dose of =< 54 Gy are eligible\r\n* Note: Patients with or without metastatic disease (excluding untreated central nervous system [CNS] metastasis), with primary pelvic disease or pelvic recurrence are eligible\r\n* Note: Patients with pelvic disease that is potentially resectable or unresectable are eligible
Eligible patients should not have had previous pelvic radiotherapy, chemotherapy or surgery for prostate cancer
Any size pelvic lymphadenopathy if it is thought to be a contributor to concurrent hydronephrosis
Previous pelvic RT
Prior pelvic radiotherapy
Patients with any prior chemotherapy or radiotherapy for pelvic malignancy
Candidate for pelvic or pelvic-inguinal radiotherapy and concurrent chemotherapy; patients undergoing preoperative chemoradiotherapy are excluded
Patient with any prior chemotherapy or radiotherapy for pelvic malignancy
Patient with any prior chemotherapy or radiotherapy for pelvic malignancy
Completion of pelvic radiotherapy treatment for this current rectal cancer or any prior pelvic radiotherapy (e.g., prior prostate or cervical cancer therapy).
Prior pelvic radiotherapy
No prior pelvic radiotherapy
Any previous pelvic radiotherapy
Patients must not have received pelvic radiotherapy as treatment for primary or recurrent disease within 1 year of the first dose of study treatment.
Subject who has undergone a prior pelvic anastomosis.
Patients must be planned to receive whole pelvic radiotherapy to a total dose of 45 Gy or greater
Patients who received prior pelvic radiotherapy for any indication
History of any major rectal or pelvic surgery or radiotherapy
Previous pelvic radiotherapy that would prevent prostate/seminal vesicle (SV) irradiation
Previous pelvic radiotherapy
Refuses or is unable to have pelvic MRI
Subjects who have had previous pelvic radiotherapy or have had chemotherapy or surgery for prostate cancer
Prior history of pelvic radiotherapy
Any size pelvic lymphadenopathy if it is thought to be a contributor to concurrent hydronephrosis
E 03. Prior isotope therapy, whole pelvic radiotherapy, or radiotherapy to >30% of bone marrow.
Patients must not have undergone a prior partial cystectomy for invasive bladder cancer; patients must not have received any prior pelvic surgery that would obviate a complete extended lymphadenectomy (e.g. aorto-femoral/iliac bypass) or for whom the surgeon feels that their ability to perform a standard or extended pelvic node dissection would be compromised
Pelvic osseous tumors ANY SIZE
Acute pelvic inflammatory disease
Has received and completed a course of pelvic radiotherapy ? 6 months prior to LAR surgery (Day 0).
Candidate for pelvic, pelvic-inguinal, or extended field radiotherapy with or without concurrent chemotherapy; patients undergoing preoperative or adjuvant chemotherapy are excluded
Patients with any prior pelvic surgery
Patients with prior history of pelvic fractures or hip replacement
Participants with a history of pelvic irradiation; or chemotherapy or radiotherapy within the preceding 14 days
Patients must have had a pelvic MRI within 28 days prior to the initiation of treatment
Prior breast, chest or pelvic radiotherapy
Patients undergoing pelvic exenteration
Radiotherapy within 28 days and abdominal/pelvic radiotherapy within 60 days prior to Day 1 of Cycle 1
Prior pelvic RT
Known or suspected active pelvic infection
Willingness to undergo pelvic radiotherapy
Contraindications to radiotherapy (including active inflammatory bowel disease or prior pelvic radiation therapy [XRT])
Extra-pelvic metastasis on any imaging or biopsy.
No prior pelvic radiotherapy
Prior hip replacement or other major pelvic surgery
Prior history of pelvic radiotherapy
Past history of pelvic radiotherapy
subjects with any contraindication to pelvic radiotherapy including, but not limited to, previous pelvic radiotherapy or brachytherapy
No prior pelvic radiation therapy
Any prior pelvic radiation
Patients who have received prior pelvic radiation or cytotoxic chemotherapy
Previous pelvic radiation for prostate cancer.
Plans for pelvic radiation while participating in the study
Previous pelvic radiation for prostate cancer.
Previous pelvic radiation
Patients with any prior pelvic radiation therapy.
Radiation therapy =< 28 days prior to registration; Note: patients with prior pelvic radiation therapy > 54 Gy are ineligible
Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
Prior pelvic radiation
Previous pelvic radiation affecting >= 25% of the bone marrow; patients who received whole pelvic radiation are excluded
Patients who had pelvic radiation within 12 months
Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
Previous pelvic radiation for prostate cancer
Previous chemotherapy or pelvic radiation therapy
No prior pelvic radiation
Previous pelvic radiation for any reason.
Prior pelvic radiation
Any therapeutic pelvic radiation
Subjects must not have had prior pelvic radiation therapy
History of prior pelvic radiation therapy
No prior pelvic radiation therapy or chemotherapy
Previous systemic chemotherapy (for any cancer) or pelvic radiation therapy
Previous pelvic radiation for bladder or prostate cancer if performed < 12 months prior to enrollment into the study
No previous history of pelvic radiation
Patients with a history of prior whole pelvic radiation
Pelvic radiation therapy
Patients who have received prior pelvic radiation
Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
Prior history of pelvic radiation therapy
Previous pelvic radiation for prior cancer
Previous pelvic radiation therapy
Prostate pelvic radiation within the past 12 months
Prior pelvic radiation therapy
An oncology research protocol requiring full pelvic radiation (i.e., 4-field box technique)
Patient must not have had radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
History of pelvic radiation
Patients must be considered able to tolerate systemic chemotherapy and pelvic radiation therapy
Previous pelvic radiation therapy
Radiation therapy to more than 25% of the bone marrow (note: whole pelvic radiation is considered to be over 25%)
Have had previous radiation of the pelvic area
Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
No prior radiation to bladder or pelvic region
Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
Patients with any prior history of whole pelvic radiation therapy (WPRT)
Patients who have had previous pelvic radiation treatment
Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
History of pelvic radiation
Prior pelvic radiation
Prior pelvic radiation for any reason
History of pelvic or rectal radiation therapy
Patients who have received any prior pelvic radiation therapy in the area of the tumor that precludes the delivery of a curative dose of pelvic radiation
Prior pelvic radiation
Patients who are referred with pelvic symptoms, a known pelvic mass, or a history of prior radiation, will be excluded from this investigation
Prior pelvic surgery or radiation
History of prior pelvic radiation
Prior history of pelvic radiation
Has received prior pelvic radiation therapy
Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
Patients who have received previous vaginal, pelvic, or abdominal irradiation
Prior pelvic or abdominal radiation
Patients who have received previous vaginal, pelvic, or abdominal irradiation
Prior history of abdominal irradiation; patients who have received prior pelvic radiation for colorectal cancer are eligible; however, prior radiation treatment plans must be reviewed prior to enrollment
Patients who have had pelvic or abdominal radiation therapy.
Previous pelvic irradiation, prostate brachytherapy
Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
History of abdominal/pelvic radiation therapy
Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
Previous pelvic radiation or prostate brachytherapy
Patients who have received previous pelvic or abdominal radiation, cytotoxic chemotherapy, or previous therapy of any kind for this malignancy or any pelvic or abdominal radiation for any prior malignancy
Received prior chemotherapy for any abdominal or pelvic tumor.
Subject with an active abdominal or pelvic infection at the operation site.
All subjects must have a radiographic assessment (chest or abdominal/pelvic CT or MRI) within 28 days prior to registration but do not need to have measurable disease.
Patients who have received previous vaginal, pelvic, or abdominal irradiation
For abdominal or pelvic irradiation: active inflammatory bowel disease
Patients with a history of pelvic or abdominal radiotherapy;
Previous pelvic irradiation, prostate brachytherapy
Large pelvic or intra-abdominal masses
History of previous abdominal or pelvic radiation therapy
Prior abdominal or pelvic RT
History of prior abdominal or pelvic radiation
Patients with prior abdominal or pelvic surgery
Major abdominal or pelvic surgery within the past 6 months
Subjects with previous pelvic or abdominal radiation therapy;